Toronto, Ontario–(Newsfile Corp. – August 3, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“Pharmadrug” or the “Company“), is pleased to announce that it has closed...
Toronto, Ontario–(Newsfile Corp. – August 2, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research,...
Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing...
Toronto, Ontario–(Newsfile Corp. – May 31, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), is pleased to announce that it has entered...
Toronto, Ontario–(Newsfile Corp. – May 27, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research,...
Selection of lead candidate from initial short-list of 6 DMT-analogues Lead candidate displays superior potency in two in vitro bioassays on two relevant human cell types...
Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancer Final study results show that oral...
Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate molecules Biocompatibility of...
Committed to the ‘pipeline-in-a-pill’ approach with PD-001 for certain cancers and COVID-19 Advances cGMP manufacturing of clinical drug supply with Southwest Research Institute Receives final positive...
Interim results show that oral cepharanthine plus cabazitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 21, the final day of...